Surface Oncology, Inc.

NasdaqCM:SURF 주식 보고서

시가총액: US$65.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Surface Oncology 미래 성장

Future 기준 확인 0/6

현재 Surface Oncology 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

9.9%

수익 성장률

9.9%

EPS 성장률

Biotechs 수익 성장28.3%
매출 성장률75.6%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트08 Sep 2023

최근 미래 성장 업데이트

Recent updates

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Nov 07
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Aug 08
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Aug 03

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

May 25

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

May 11
News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 23
Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Jan 18

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Nov 11
Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Surface Oncology: Staying The Course

Oct 24

Surface Oncology: A Diverse, But Early Pipeline

Jul 13

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Jun 07
Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Surface Oncology EPS beats by $0.04, beats on revenue

May 05

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Mar 15
Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 16
Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets

Dec 09

What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Dec 08
What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Surface Oncology shares rise 13% on Fast Track tag for SRF388

Nov 11

수익 및 매출 성장 예측

NasdaqCM:SURF - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202516-75N/AN/A2
12/31/2024N/A-90N/AN/A2
12/31/2023N/A-90N/AN/A1
6/30/2023N/A-93-84-84N/A
3/31/2023N/A-90-60-59N/A
12/31/202230-64-60-60N/A
9/30/202230-66-54-54N/A
6/30/202231-63-50-50N/A
3/31/202231-57-67-67N/A
12/31/20213-78-62-62N/A
9/30/202190132626N/A
6/30/202190173131N/A
3/31/202189212727N/A
12/31/2020126593030N/A
9/30/202039-24-56-56N/A
6/30/202039-25-60-60N/A
3/31/202040-28-58-57N/A
12/31/201915-55-62-60N/A
9/30/201925-44-63-61N/A
6/30/201926-44-61-58N/A
3/31/201928-35-65-63N/A
12/31/201859-7-15-13N/A
9/30/201852-18-15-14N/A
6/30/201853-15-12-11N/A
3/31/201857-132122N/A
12/31/201713-45-14-12N/A
9/30/201712-36-13-11N/A
12/31/20167-17N/A41N/A

애널리스트 미래 성장 예측

수입 대 저축률: SURF 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: SURF 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: SURF 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: SURF 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: SURF 은(는) 내년에 수익이 없을 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: SURF 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견